The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
13
09
2022
accepted:
01
02
2023
revised:
24
01
2023
medline:
28
4
2023
pubmed:
25
2
2023
entrez:
24
2
2023
Statut:
ppublish
Résumé
The immune peptidome of OPSCC has not previously been studied. Cancer-antigen specific vaccination may improve clinical outcome and efficacy of immune checkpoint inhibitors such as PD1/PD-L1 antibodies. Mapping of the OPSCC HLA ligandome was performed by mass spectrometry (MS) based analysis of naturally presented HLA ligands isolated from tumour tissue samples (n = 40) using immunoaffinity purification. The cohort included 22 HPV-positive (primarily HPV-16) and 18 HPV-negative samples. A benign reference dataset comprised of the HLA ligandomes of benign haematological and tissue datasets was used to identify tumour-associated antigens. MS analysis led to the identification of naturally HLA-presented peptides in OPSCC tumour tissue. In total, 22,769 peptides from 9485 source proteins were detected on HLA class I. For HLA class II, 15,203 peptides from 4634 source proteins were discovered. By comparative profiling against the benign HLA ligandomic datasets, 29 OPSCC-associated HLA class I ligands covering 11 different HLA allotypes and nine HLA class II ligands were selected to create a peptide warehouse. Tumour-associated peptides are HLA-presented on the cell surfaces of OPSCCs. The established warehouse of OPSCC-associated peptides can be used for downstream immunogenicity testing and peptide-based immunotherapy in (semi)personalised strategies.
Sections du résumé
BACKGROUND
The immune peptidome of OPSCC has not previously been studied. Cancer-antigen specific vaccination may improve clinical outcome and efficacy of immune checkpoint inhibitors such as PD1/PD-L1 antibodies.
METHODS
Mapping of the OPSCC HLA ligandome was performed by mass spectrometry (MS) based analysis of naturally presented HLA ligands isolated from tumour tissue samples (n = 40) using immunoaffinity purification. The cohort included 22 HPV-positive (primarily HPV-16) and 18 HPV-negative samples. A benign reference dataset comprised of the HLA ligandomes of benign haematological and tissue datasets was used to identify tumour-associated antigens.
RESULTS
MS analysis led to the identification of naturally HLA-presented peptides in OPSCC tumour tissue. In total, 22,769 peptides from 9485 source proteins were detected on HLA class I. For HLA class II, 15,203 peptides from 4634 source proteins were discovered. By comparative profiling against the benign HLA ligandomic datasets, 29 OPSCC-associated HLA class I ligands covering 11 different HLA allotypes and nine HLA class II ligands were selected to create a peptide warehouse.
CONCLUSION
Tumour-associated peptides are HLA-presented on the cell surfaces of OPSCCs. The established warehouse of OPSCC-associated peptides can be used for downstream immunogenicity testing and peptide-based immunotherapy in (semi)personalised strategies.
Identifiants
pubmed: 36823366
doi: 10.1038/s41416-023-02197-y
pii: 10.1038/s41416-023-02197-y
pmc: PMC9949688
doi:
Substances chimiques
Peptides
0
HLA Antigens
0
Antigens, Neoplasm
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1777-1787Informations de copyright
© 2023. The Author(s).
Références
Nature. 2020 Sep;585(7823):107-112
pubmed: 32728218
Blood. 2019 Feb 7;133(6):550-565
pubmed: 30530751
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33060146
Genome Med. 2019 Apr 30;11(1):28
pubmed: 31039795
Expert Rev Vaccines. 2013 Oct;12(10):1211-7
pubmed: 24090147
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Acta Neuropathol. 2018 Jun;135(6):923-938
pubmed: 29557506
Int J Cancer. 2005 Jan 10;113(2):276-83
pubmed: 15386416
Lancet. 2019 Jan 12;393(10167):156-167
pubmed: 30509740
Science. 2017 Apr 14;356(6334):200-205
pubmed: 28408606
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
CA Cancer J Clin. 2017 Mar;67(2):122-137
pubmed: 28128848
BMC Genomics. 2008 Oct 16;9:488
pubmed: 18925949
N Engl J Med. 2009 Nov 5;361(19):1838-47
pubmed: 19890126
Nat Commun. 2021 Dec 22;12(1):7348
pubmed: 34937871
BMC Bioinformatics. 2014 Aug 29;15:293
pubmed: 25176396
Clin Cancer Res. 2019 Dec 15;25(24):7405-7412
pubmed: 31444248
Clin Cancer Res. 2022 Feb 1;28(3):468-478
pubmed: 34667025
J Clin Oncol. 2006 Dec 20;24(36):5630-6
pubmed: 17179101
Clin Cancer Res. 2022 Apr 1;28(7):1345-1352
pubmed: 35338369
Int J Cancer. 2014 Aug 15;135(4):830-42
pubmed: 24415578
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Genome Med. 2020 Mar 30;12(1):32
pubmed: 32228647
Nat Methods. 2007 Nov;4(11):923-5
pubmed: 17952086
Int J Cancer. 2019 Dec 15;145(12):3436-3444
pubmed: 31407331
J Natl Cancer Inst. 2000 May 3;92(9):709-20
pubmed: 10793107
Bioinformatics. 2016 Feb 15;32(4):511-7
pubmed: 26515819
Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):E9942-E9951
pubmed: 29093164
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Clin Cancer Res. 2018 Feb 1;24(3):634-647
pubmed: 29018052
Brief Bioinform. 2021 May 20;22(3):
pubmed: 32954413
Nature. 2019 Jan;565(7738):240-245
pubmed: 30568303
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
Int J Cancer. 2011 Jan 15;128(2):379-89
pubmed: 20473854
Nat Rev Cancer. 2016 Apr;16(4):219-33
pubmed: 26965076
JAMA Oncol. 2019 Jan 1;5(1):67-73
pubmed: 30267032
Immunogenetics. 1999 Nov;50(3-4):213-9
pubmed: 10602881
Clin Cancer Res. 2020 Oct 1;26(19):5140-5152
pubmed: 32665297
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450
pubmed: 30395289
Nature. 2008 Nov 6;456(7218):53-9
pubmed: 18987734
BMC Bioinformatics. 2006 Mar 17;7:153
pubmed: 16545123
Tissue Antigens. 2014 Feb;83(2):65-75
pubmed: 24447174
Nucleic Acids Res. 2019 Jan 8;47(D1):D339-D343
pubmed: 30357391
Int J Cancer. 2006 Apr 15;118(8):1984-91
pubmed: 16284959
Methods Mol Biol. 2013;960:145-157
pubmed: 23329485
Ann Oncol. 2011 May;22(5):1071-1077
pubmed: 21317223
JCI Insight. 2018 Apr 19;3(8):
pubmed: 29669936
J Transl Med. 2013 Apr 04;11:88
pubmed: 23557172
JAMA Oncol. 2020 Oct 1;6(10):1563-1570
pubmed: 32852531
Nucleic Acids Res. 2020 Jan 8;48(D1):D783-D788
pubmed: 31722398
Blood. 2015 Sep 3;126(10):1203-13
pubmed: 26138685
Front Microbiol. 2018 Jun 05;9:1172
pubmed: 29922260
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33023982
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Int J Cancer. 2012 Jul 15;131(2):E74-85
pubmed: 22020783
J Neurooncol. 2013 Feb;111(3):285-94
pubmed: 23263746
Virology. 2010 Nov 10;407(1):137-42
pubmed: 20813390
Int J Oral Surg. 1983 Dec;12(6):418-24
pubmed: 6325356
Future Oncol. 2020 Jun;16(18):1235-1243
pubmed: 32490686